These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2852947)

  • 1. Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer.
    Green JA; Tarpey AW; Warenius HM
    Acta Oncol; 1988; 27(6b):819-22. PubMed ID: 2852947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
    Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
    J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
    Minami H; Horio Y; Sakai S; Saka H; Shimokata K
    Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
    Miller AA; Tolley EA; Niell HB; Stewart CF; Griffin JP
    Cancer Chemother Pharmacol; 1992; 31(2):161-6. PubMed ID: 1333371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A limited sampling method for estimation of the etoposide area under the curve.
    Strömgren AS; Sørensen BT; Jakobsen P; Jakobsen A
    Cancer Chemother Pharmacol; 1993; 32(3):226-30. PubMed ID: 7684658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacodynamics of continuous-infusion etoposide.
    Miller AA; Stewart CF; Tolley EA
    Cancer Chemother Pharmacol; 1990; 25(5):361-6. PubMed ID: 2155063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting etoposide toxicity: relationship to organ function and protein binding.
    Joel SP; Shah R; Clark PI; Slevin ML
    J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
    Joel SP; Ellis P; O'Byrne K; Papamichael D; Hall M; Penson R; Nicholls S; O'Donnell C; Constantinou A; Woodhull J; Nicholson M; Smith I; Talbot D; Slevin M
    J Clin Oncol; 1996 Jun; 14(6):1903-12. PubMed ID: 8656259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients.
    Katoh O; Yamada H; Hiura K; Aoki Y; Kuroki S
    J Clin Pharmacol; 1991 Dec; 31(12):1155-60. PubMed ID: 1662234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.
    Chatelut E; Chevreau C; Blancy E; Lequellec A; Canal P; Roche H; Houin G; Bugat R
    Cancer Chemother Pharmacol; 1990; 26(5):365-8. PubMed ID: 2170043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
    Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
    Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer.
    Minami H; Shimokata K; Saka H; Saito H; Ando Y; Senda K; Nomura F; Sakai S
    J Clin Oncol; 1993 Aug; 11(8):1602-8. PubMed ID: 8336196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.